Bayesian hierarchical modeling and the integration of heterogeneous information on the effectiveness of cardiovascular therapies

Circulation: Cardiovascular Quality and Outcomes

Volumn 4, Issue 6, 2011, Pages 657-666

  Kwok, Heemun ^a   Lewis, Roger J ^b,c,d,e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^e Berry Consultants   (United States)

Author keywords

Comparative effectiveness research; Multilevel analysis; Practice guidelines

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; EVEROLIMUS; PACLITAXEL; PLACEBO; PREDNISONE; TISSUE PLASMINOGEN ACTIVATOR;

BAYES THEOREM; BAYESIAN HIERARCHICAL MODELING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; COMPARATIVE EFFECTIVENESS; CONGESTIVE CARDIOMYOPATHY; DRUG ELUTING STENT; ENDOMETRIUM BIOPSY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYOCARDITIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

BAYES THEOREM; BIOMETRY; CARDIOMYOPATHIES; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFORMATION MANAGEMENT; META-ANALYSIS AS TOPIC; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; RESEARCH DESIGN; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 84856083774     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.111.960724     Document Type: Review

References (40)

1. Kehdi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goehart D, Smith PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomized trial. Lancet. 2010;375:201-209.
2. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-1674.
3. DeMets DL. Lessons learned from recent cardiovascular clinical trials: part I. Circulation. 2002;106:746-751.
4. Department of Health and Human Services. Draft definition of comparative effectiveness research for the Federal Coordinating Council January 20, 2011. www.hhs.gov/recovery/programs/cer/draftdefinition.html.
5. Gatsonis C. The promise and realities of comparative effectiveness research. Stat Med. 2010;29:1977-1981.
6. Tunis SR, Benner J, McClellan M. Comparative effectiveness research: policy context, methods development and research infrastructure. Stat Med. 2010;29:1963-1976.
7. Normand SL, McNeil BJ. What is evidence? Stat Med. 2010;29: 1985-1988.
8. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172: 137-159.
9. Raudenbush SW, Bryk AS. Empirical Bayes meta-analysis. J Educ Behav Stat. 1985;10:75-98.
10. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res. 2001;10:277-303. (Pubitemid 32691157)
11. Browne WJ, Draper D. A comparison of Bayesian and likelihood-based methods for fitting multilevel models. Bayesian Anal. 2006;1:473-514.
12. Greenland S. Principles of multilevel modeling. Int J Epidemiol. 2000; 29:158-167.
13. Lipsky AM, Gausche-Hill M, Vienna M, Lewis RJ. The importance of "shrinkage" in subgroup analyses. Ann Emerg Med. 2010;55:544-552.
14. Normand ST. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med. 1999;18:321-359.
15. Sutton AJ, Higgins JPT. Recent developments in meta-analysis. Stat Med. 2008;27:625-650. (Pubitemid 351278810)
16. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration; 2011. June 22, 2011. www.cochrane-handbook.org.
17. Parrillo JE, Cunnion RE, Epstein SE, Parker MM, Suffredini AF, Brenner M, Schaer GL, Palmeri ST, Cannon RO, Alling D, Wittes JT, Ferrans J, Rodriguez ER, Fauci AS. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med. 1989;321: 1061-1068. (Pubitemid 19256658)
18. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333:269-275.
19. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, Zembala M, Polonski L, Rozek MM, Wod-niecki J. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39-45. (Pubitemid 32623287)
20. Cooper LT. Myocarditis. N Engl J Med. 2009;360:1526-1538.
21. Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. 2006;113:876-890.
22. Parrillo JE. Inflammatory cardiomyopathy (myocarditis): which patients should be treated with anti-inflammatory therapy? Circulation. 2001;104:4-6. (Pubitemid 32623279)
23. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30:1995-2002.
24. Agresti A. On logit confidence intervals for the odds ratio with small samples. Biometrics. 1999;55:597-602. (Pubitemid 29302589)
25. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. 2nd ed. Boca Raton, FL: Chapman and Hall/CRC; 2003.
26. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7:457-472.
27. Austin PC. Estimating multilevel logistic regression models when the number of clusters is low: a comparison of different statistical software procedures. Int J Biostat. 2010;6:pii.
28. Gelman A. Prior distributions for variance parameters in hierarchical models. Bayesian Anal. 2006;1:515-533.
29. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med. 2005;24:2401-2428. (Pubitemid 41093922)
30. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine: reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189-2194.
31. Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176-186. (Pubitemid 40091809)
32. Parker A, Naylor C. Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. Am Heart J. 2000;139: 952-961. (Pubitemid 30390322)
33. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
34. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA stroke trial. Stroke. 1997;28:2119-2125.
35. Kwiatkowski T, Libman R, Tilley BC, Lewandowski C, Grotta JC, Lyden P, Levine SR, Brott T; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator stroke study. Ann Emerg Med. 2005;45:377-384. (Pubitemid 43181003)
36. Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, Christianson TJ. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke. 2004;35:2418-2424. (Pubitemid 39328073)
37. Marler J, Tilley B, Lu M, Brott T, Lyden P, Grotta J, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley EC, Lewandowski CA, Kwiat-kowski TP. Early stroke treatment associated with better outcome. Neu¬rology. 2000;55:1649-1655.
38. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: The National Institute of Neurological Disorders and Stroke rt-PA Stroke study experience. Ann Emerg Med. 2005;46:243-252.
39. Tanne D. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the multicenter rt-PA acute stroke survey. Circulation. 2002;105:1679-1685. (Pubitemid 34298612)
40. Jones HE, Ohlssen DI, Neuenschwander B, Racine A, Branson M. Bayesian models for subgroup analysis in clinical trials. Clin Trials. 2011;8:129-143.